Koers Bachem Holding AG Swiss Exchange
Aandelen
BANB
CH0012530207
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 620 mln. 678 mln. 633 mln. | Omzet 2025 * | 811 mln. 887 mln. 828 mln. | Marktkapitalisatie | 6,07 mld. 6,64 mld. 6,2 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 127 mln. 139 mln. 130 mln. | Nettowinst (verlies) 2025 * | 160 mln. 175 mln. 163 mln. | EV/omzet 2024 * | 9,69 x |
Nettoliquiditeiten 2024 * | 64,89 mln. 71 mln. 66,25 mln. | Nettoschuld 2025 * | 74,85 mln. 81,89 mln. 76,41 mln. | EV/omzet 2025 * | 7,58 x |
K/w-verhouding 2024 * |
50,5
x | K/w-verhouding 2025 * |
38,3
x | Werknemers | 2.006 |
Dividendrendement 2024 * |
1,06% | Dividendrendement 2025 * |
1,15% | Vrij verhandelbaar | 94,31% |
Recentste transcriptie over Bachem Holding AG
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Meier
CEO | Chief Executive Officer | 56 | 01-01-19 |
Alain Schaffter
DFI | Director of Finance/CFO | 47 | 01-02-21 |
Ralph Schönleber
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-03 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Peter Grogg
BRD | Director/Board Member | 82 | - |
Kuno Sommer
CHM | Chairman | 68 | 25-04-12 |
Director/Board Member | 51 | 13-04-11 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.15% | 18 M€ | +3,04% | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+4,09% | 43,84 mld. | |
+47,07% | 41,25 mld. | |
+9,45% | 41,68 mld. | |
-10,92% | 27,04 mld. | |
+9,32% | 25,53 mld. | |
-24,87% | 18,18 mld. | |
+29,70% | 12,29 mld. | |
+1,28% | 12,29 mld. | |
+7,78% | 11,15 mld. |